Tue, Sep 16, 2014, 1:31 AM EDT - U.S. Markets open in 7 hrs 59 mins


% | $
Quotes you view appear here for quick access.

Peregrine Pharmaceuticals, Inc. Message Board

  • asmarterwookie asmarterwookie Feb 14, 2013 8:11 PM Flag

    Dear Stockholders, (from the2012 Annual Report)

    Dear Stockholders,
    This is a truly transformative time for Peregrine.
    We are transitioning from an early-stage research organization to a late-stage drug development company, thanks
    to an expanding product pipeline that now includes two Phase III-ready programs, exceptional proof-of-concept
    clinical data for our lead product candidate bavituximab and a record-breaking revenue year for our contract
    manufacturing business. Taken together, this has been an exciting year of growth that has set the stage for success
    now and into the future.
    By diligently executing our strategy, today we are positioned with two advanced programs from our oncologyfocused
    pipeline ready for Phase III development. Over the last year, we made great strides in exploring the
    potential of our proprietary phosphatidylserine (PS)-targeting platform including our lead PS-targeting antibody
    bavituximab and in advancing our other business goals. Achievements over the past year included:...

    Best of Better Data and Luck


    Sentiment: Strong Buy

1.50-0.05(-3.23%)Sep 15 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Avanir Pharmaceuticals, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT
JDS Uniphase Corporation
NasdaqGSMon, Sep 15, 2014 4:15 PM EDT
21Vianet Group, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT